Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Robert C. Grant

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9821-0377; OpenAlex author ID A5042670619, A5087178283, A5132866574, A5135365842. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
135
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 5 papers · 2021: 5 papers · 2022: 6 papers · 2023: 3 papers · 2024: none · 2025: 7 papers, 1 trial · 2026: 8 papers

Papers 44

  1. AI-Based Segmentation Reduces the Retrospective Miss Rate of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/s10278-025-01792-0↗
  2. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  3. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  4. Examination of DNA methylation patterns in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10421877/v1↗
  5. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Co-author DOI 10.3389/frai.2026.1873681↗
  6. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Last author DOI 10.64898/2026.04.07.717011↗
  7. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  8. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Last author DOI 10.64898/2026.08.24.26360900↗
  9. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  10. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  11. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  12. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  13. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  14. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  15. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  16. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  17. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
  18. hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
  19. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Co-author DOI 10.1007/s00330-021-08314-w↗
  20. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-022-09057-y↗
  21. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  22. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  23. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.860767↗
  24. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Co-author DOI 10.6004/jnccn.2021.7107↗
  25. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants. First author DOI 10.1002/gcc.22947↗
  26. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Last author DOI 10.1016/j.ctrv.2021.102310↗
  27. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Co-author DOI 10.1038/s41598-021-94544-3↗
  28. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  29. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  30. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  31. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  32. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome. Co-author DOI 10.1136/gutjnl-2019-318217↗
  33. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3724↗
  34. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1439↗
  35. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  36. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  37. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  38. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  39. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  40. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.030↗
  41. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Co-author DOI 10.1053/j.gastro.2014.11.042↗
  42. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2014.59.7401↗
  43. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. Co-author DOI 10.1186/1479-7364-7-11↗
  44. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. Co-author DOI 10.1007/s11605-011-1781-6↗

Trials 1

  1. Using Tumor Models to Determine Treatments Principal investigator NCT06813079↗

Closest collaborators

The 25 strongest of 135 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 42 shared papers, 2012–2026 · strength 5.31
  2. Grainne Mary O'Kane · 32 shared papers, 2018–2026 · strength 4.53
  3. Faiyaz Notta · 29 shared papers, 2017–2026 · strength 4.15
  4. Jennifer Jane Knox · 30 shared papers, 2018–2026 · strength 4.13
  5. Sandra Elisabeth Fischer · 21 shared papers, 2018–2026 · strength 2.51
  6. George Zogopoulos · 19 shared papers, 2016–2025 · strength 1.92
  7. Erica S. Tsang · 9 shared papers, 2025–2026 · strength 1.70
  8. Ayelet Borgida · 19 shared papers, 2012–2026 · strength 1.68
  9. Barbara T. Grünwald · 11 shared papers, 2020–2026 · strength 1.65
  10. Spring Holter · 15 shared papers, 2012–2026 · strength 1.39
  11. Michelle Chan‐Seng‐Yue · 11 shared papers, 2016–2026 · strength 1.35
  12. Yifan Wang · 11 shared papers, 2020–2025 · strength 1.25
  13. Eugenia Flores Figueroa · 7 shared papers, 2020–2026 · strength 1.19
  14. David Arthur Tuveson · 6 shared papers, 2020–2026 · strength 0.86
  15. Daniel John Renouf · 7 shared papers, 2020–2025 · strength 0.83
  16. Masoom A. Haider · 5 shared papers, 2012–2026 · strength 0.82
  17. David Henault · 3 shared papers, 2026 · strength 0.77
  18. Raymond Jang · 5 shared papers, 2021–2025 · strength 0.75
  19. Kai Duan · 4 shared papers, 2021–2025 · strength 0.65
  20. James Biagi · 5 shared papers, 2020–2026 · strength 0.64
  21. Sheron Perera · 4 shared papers, 2022–2025 · strength 0.61
  22. Yuanchang Fang · 3 shared papers, 2025–2026 · strength 0.57
  23. Malcolm J. Moore · 7 shared papers, 2012–2025 · strength 0.56
  24. Andrew Victor Biankin · 3 shared papers, 2018–2026 · strength 0.54
  25. Eileen Mary O'Reilly · 3 shared papers, 2025–2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.